Streetbeat News

Price Targets

CRNX

HC Wainwright & Co. analyst Douglas Tsao reinstated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:15 am

CHRS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:15 am

CTV

Needham analyst Laura Martin reiterated a Buy rating on Innovid (NYSE:CTV) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:14 am

TBLA

Needham analyst Laura Martin reiterated a Buy rating on Taboola.com (NASDAQ:TBLA) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:13 am

ALLO

HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $23 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:11 am

SURF

HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Surface Oncology (NASDAQ:SURF) from Buy to Neutral and set a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:09 am

PERI

Needham analyst Laura Martin reiterated a Buy rating on Perion Network (NASDAQ:PERI) and maintained a $42 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:06 am

OB

Needham analyst Laura Martin reiterated a Buy rating on Outbrain (NASDAQ:OB) and maintained a $5.5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:04 am

TRMR

Needham analyst Laura Martin reiterated a Buy rating on Tremor Intl (NASDAQ:TRMR) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:04 am